John Freshley has 20+ years in leadership roles of start-up companies. His expertise spans the assembly of multi-disciplinary leadership teams, product and business strategy development, partnership development, and fundraising. John joined ONL Therapeutics in 2013 after serving the company as a mentor-in-residence through the technology transfer office at the University of Michigan.
Prior to ONL, John was chief business officer of Compendia Bioscience through its acquisition by Life Technologies in 2012. He launched the company in 2006 with co-founders from the University of Michigan and served as its interim chief executive officer. In this role, he assembled the management team, secured early funding and the company’s initial round of customers. Previously, John had been president and chief executive officer of Genetics Squared (now Everist Health).